[go: up one dir, main page]

PE20080934A1 - Proceso para sintetizar compuestos de piperazina-piperidina - Google Patents

Proceso para sintetizar compuestos de piperazina-piperidina

Info

Publication number
PE20080934A1
PE20080934A1 PE2007000705A PE2007000705A PE20080934A1 PE 20080934 A1 PE20080934 A1 PE 20080934A1 PE 2007000705 A PE2007000705 A PE 2007000705A PE 2007000705 A PE2007000705 A PE 2007000705A PE 20080934 A1 PE20080934 A1 PE 20080934A1
Authority
PE
Peru
Prior art keywords
independently
formula
piperazine
compound
piperidin
Prior art date
Application number
PE2007000705A
Other languages
English (en)
Inventor
Weiguo Liu
Vladimir Dragan
Henry Lee Strong
Yanzhong Wu
Zhixin Wen
Jessica Kangping Liang
Haris Durutlic
Karen Wiggins Sutherland
Anthony Scott Pilcher
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080934A1 publication Critical patent/PE20080934A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN PROCESO PARA SINTERIZAR UN COMPUESTO DE PIPERAZINA-PIPERIDINA QUE COMPRENDE EN HACER REACCIONAR UN COMPUESTO PIRAZOLO-QUINOLONA DE FORMULA (I), EN DONDE R1, R2, R3, R4, R5 Y R6 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), HALOGENO, CF3, ENTRE OTROS; Ra Y Rb SON INDEPENDIENTEMENTE H O CH3; CON UN COMPUESTO DE PIPERIDIN-4-ONA DE FORMULA (IV) EN DONDE DE R7 A R12 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), ENTRE OTROS; Y EN PRESENCIA DE TOLUENO Y BAJO CONDICIONES EFECTIVAS PARA CAUSAR AMINACION REDUCTIVA AL PIPERIDIN CARBONILO Y POR ELLO PROPORCIONAR UN COMPUESTO PIPERAZINA-PIPERIDINA DE FORMULA (V). ESTE PROCESO PERMITE LA PRODUCCION MAS SEGURA Y AMBIENTALMENTE TOLERADA DE ESTOS COMPUESTOS, QUE SON UTILES COMO AGENTES DE ENLACE 5-HT1A, PARTICULARMENTE COMO ANTAGONISTAS O AGONISTAS DEL RECEPTOR 5-HT1A
PE2007000705A 2006-06-09 2007-06-07 Proceso para sintetizar compuestos de piperazina-piperidina PE20080934A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81214806P 2006-06-09 2006-06-09

Publications (1)

Publication Number Publication Date
PE20080934A1 true PE20080934A1 (es) 2008-09-10

Family

ID=38669840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000705A PE20080934A1 (es) 2006-06-09 2007-06-07 Proceso para sintetizar compuestos de piperazina-piperidina

Country Status (12)

Country Link
US (1) US20080058523A1 (es)
EP (1) EP2035384A2 (es)
JP (1) JP2009539849A (es)
CN (1) CN101466680A (es)
AR (1) AR061303A1 (es)
AU (1) AU2007258552A1 (es)
BR (1) BRPI0712153A2 (es)
CA (1) CA2650934A1 (es)
MX (1) MX2008015050A (es)
PE (1) PE20080934A1 (es)
TW (1) TW200808730A (es)
WO (1) WO2007146072A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
CN105037389B (zh) * 2015-06-09 2017-09-05 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60011570T2 (de) * 1999-01-07 2004-11-25 Wyeth Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE10043659A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7276603B2 (en) * 2003-05-02 2007-10-02 Wyeth Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use
MY179926A (en) * 2003-12-08 2020-11-19 Wyeth Corp Process for the preparation of tubulin inhibitors
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor

Also Published As

Publication number Publication date
AU2007258552A1 (en) 2007-12-21
CN101466680A (zh) 2009-06-24
WO2007146072A2 (en) 2007-12-21
AR061303A1 (es) 2008-08-20
BRPI0712153A2 (pt) 2012-01-24
WO2007146072A3 (en) 2008-05-29
US20080058523A1 (en) 2008-03-06
CA2650934A1 (en) 2007-12-21
EP2035384A2 (en) 2009-03-18
TW200808730A (en) 2008-02-16
JP2009539849A (ja) 2009-11-19
MX2008015050A (es) 2008-12-05

Similar Documents

Publication Publication Date Title
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20141935A1 (es) Compuestos de dioxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
AR064824A1 (es) Derivados de espirocromanona sustituidos
SG163585A1 (en) Melanocortin receptor ligands
AR116300A1 (es) Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo
AR083399A1 (es) Proceso para la preparacion de cicloheptapiridina como antagonista del receptor de cgrp
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
CR9589A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento
PE20081472A1 (es) Compuestos de pirazolina
UY30146A1 (es) Radioligandos novedosos
AR060813A1 (es) Moduladores de mglur5 iii
TNSN07463A1 (en) Process for the synthesis of organic compounds
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
MY150062A (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
TW200600494A (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
CR10540A (es) Derivados ciclopropil amina
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
PE20080934A1 (es) Proceso para sintetizar compuestos de piperazina-piperidina
ATE535494T1 (de) Wasserstoffspeichermaterial
PE20141168A1 (es) Derivados de pirazolidin-3-ona
MX2009008221A (es) Antagonista de receptor de cromeno s1p1.
AR068062A1 (es) Sulfonas ciclicas sustituidas por amino- bencilo utiles como inhibidores de bace
NI200900152A (es) Nuevo procedimiento de síntesis de la agomelatina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal